Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

Accuray opens new European training hub in Switzerland

EditorNatashya Angelica
Published 19/04/2024, 03:04 am

MADISON, Wis. - Accuray (NASDAQ:ARAY) Incorporated (NASDAQ: ARAY) has expanded its global network of training centers with the inauguration of a new facility in Genolier, Switzerland, the company announced today. This center is aimed at providing advanced education and training on the Accuray CyberKnife® and Radixact® Radiation Treatment Delivery Systems, as well as the Accuray Precision® Treatment Planning System.

The Switzerland site joins Accuray's existing hubs in Madison, Tokyo, and Tianjin, enhancing the company's efforts to advance patient care in the field of radiosurgery and radiotherapy. The Genolier location is strategically placed to serve as the European education hub, offering a suite of educational opportunities for medical professionals.

Equipped with simulation facilities for hands-on training, the center will cater to the needs of neurosurgeons, radiation oncologists, medical physicists, dosimetrists, and radiotherapy technologists. The facility also boasts advanced technology in its meeting rooms to facilitate seminars, workshops, and educational events.

Suzanne Winter, president and CEO of Accuray, emphasized the company's role in supporting medical teams to access radiotherapy in their communities, thereby driving optimal patient care. The partnership with Genolier Innovation Hub is expected to provide an exceptional site for high-quality training and learning from renowned faculty.

Accuray's CyberKnife and Radixact Systems are designed to deliver precise and accurate treatments while minimizing exposure to healthy tissue, reducing the risk of side effects. These systems are intended to manage a full spectrum of cancer cases and neurologic disorders, offering options for both initial treatment and retreatment.

The company, headquartered in Madison, Wisconsin, is known for its commitment to innovation in radiation therapy for oncology and neuro-radiosurgery. The Genolier training facility is part of Accuray's dedication to enhancing radiation therapy and improving patient outcomes. The grand opening of the Genolier Innovation Hub, which houses the training center, is scheduled for later this year.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

This expansion underscores Accuray's commitment to providing state-of-the-art clinical education to healthcare professionals, with the goal of improving patient care globally. The information is based on a press release statement from Accuray Incorporated.

InvestingPro Insights

As Accuray Incorporated (NASDAQ: ARAY) continues to expand its global training network with the opening of its new facility in Switzerland, investors and industry observers are closely monitoring the company's financial health and market performance. The latest data from InvestingPro provides insights into the company's current valuation and market sentiment.

Accuray has a market capitalization of 217.18 million USD, reflecting its position in the market. Despite the company's innovative strides in radiation therapy, analysts have revised their earnings downwards for the upcoming period, indicating potential challenges ahead. Furthermore, the company is not expected to be profitable this year, which could be a concern for investors looking for short-term gains.

The company has been trading near its 52-week low, with a price to book ratio over the last twelve months as of Q2 2024 at 4.56, suggesting that the market may have concerns about the company's asset valuation. Additionally, Accuray's price performance has been under pressure, with a year-to-date price total return in 2024 of -22.61%.

InvestingPro Tips reveal that Accuray is also trading at high EBIT and EBITDA valuation multiples, which may indicate that its earnings before interest and taxes are priced at a premium compared to the industry average. This could be a point of analysis for potential investors considering the company's financials in relation to its growth prospects.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

For those interested in a deeper dive into Accuray's financials and market performance, InvestingPro offers additional insights and metrics. There are 6 more InvestingPro Tips available for Accuray, which can be accessed by visiting https://www.investing.com/pro/ARAY. To enhance your investing strategy with these insights, use coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.